Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

An In Vivo Model for Postinflammatory Hyperpigmentation

NCT02905903 · View on ClinicalTrials.gov ↗

Study Summary

Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that occurs after cutaneous inflammation or injury that frequently affects darker skinned populations. Previously, a model of 35% TCA-induced PIH was validated against acne induced PIH, which has value in product testing for the treatment of PIH. In this second phase of the study, the investigators would like to determine if a lower concentration of TCA-induced PIH is comparable to acne-induced PIH.

Interventions

  • DRUG Tricholoacetic Acid (TCA)

Study Locations (1)

Michigan

  • Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard, — Detroit

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-02-14
Est. Completion 2019-06-21
Phase NA

Sponsor

Henry Ford Health System

171 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02905903

The ClinicalTrials.gov registry entry for NCT02905903 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 171 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Post-inflammatory Hyperpigmentation appearing as the primary indexed condition, and to 1 intervention — of which Tricholoacetic Acid (TCA) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02905903 reports 1 study location spanning 1 distinct geographic area — top geographies include Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02905903 about?

NCT02905903 is a clinical study titled "An In Vivo Model for Postinflammatory Hyperpigmentation". Post-inflammatory hyperpigmentation (PIH) is an acquired hypermelanosis that occurs after cutaneous inflammation or injury that frequently affects darker skinned populations. Previously, a model of 35% TCA-induced PIH was validated against acne induced PIH, which has value in product testing for the...

What is the current status of trial NCT02905903?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-02-14. Estimated completion is 2019-06-21.

What conditions does trial NCT02905903 study?

This clinical trial studies the following conditions: Post-inflammatory Hyperpigmentation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02905903?

The interventions under investigation include: Tricholoacetic Acid (TCA) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02905903?

This trial is sponsored by Henry Ford Health System, which has 171 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02905903 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial